ELOQUENT-3 Trial: Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma Final Overall Survival Analysis

被引：0

作者：

Raab, Marc-Steffen ^{[1
]}

Dimopoulos, Meletios ^{[2
]}

Dytfeld, Dominik ^{[3
]}

Grosicki, Sebastian ^{[4
]}

Moreau, Philippe ^{[5
]}

Takezako, Naoki ^{[6
]}

Hori, Mitsuo ^{[7
]}

Leleu, Xavier ^{[8
]}

Leblanc, Richard ^{[9
]}

Suzuki, Kenshi ^{[10
]}

Richardson, Paul G. ^{[11
]}

Mckiver, Mihaela Popa ^{[12
]}

Jou, Ying-Ming ^{[12
]}

Yao, David ^{[12
]}

Das, Prianka ^{[12
]}

San-Miguel, Jesus ^{[13
]}

机构：

[1] Heidelberg Univ Hosp, Dept Med 5, Heidelberg, Germany

[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

[3] Poznan Univ Med Sci, Dept Hematol & Bone Marrow Transplantat, Poznan, Poland

[4] Silesian Med Univ, Katowice, Poland

[5] Univ Hosp, Nantes, France

[6] Natl Hosp Org Disaster Med Ctr, Dept Hematol, Tokyo, Japan

[7] Ibaraki Cent Hosp, Dept Hematol, Kasama, Japan

[8] Ctr Hosp Univ Poitiers Miletrie, Poitiers, France

[9] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada

[10] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan

[11] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA

[12] Bristol Myers Squibb, Princeton, NJ USA

[13] Clin Univ Navarra CUUN, Inst Invest Sanitaria Navarra IDISNA, Ctr Invest Med Aplicada, Ctr Invest Biomed Red Canc CIBERONC, Pamplona, Spain

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

971

引用

页码：174 / 174

页数：1

共 50 条

[1] ELOQUENT-3 study: elotuzumab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma - final analysis of overall survival (OS)
Raab, M. S.
Dimopoulos, M.
Dytfeld, D.
Grosicki, S.
Moreau, P.
Takezako, N.
Hori, M.
Leleu, X.
LeBlanc, R.
Suzuki, K.
Richardson, P. G.
Popa McKiver, M.
Jou, Y. -M.
Yao, D.
Das, P.
San-Miguel, J.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 87 - 87
[2] Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
Dimopoulos, Meletios A.
Dytfeld, Dominik
Grosicki, Sebastian
Moreau, Philippe
Takezako, Naoki
Hori, Mitsuo
Leleu, Xavier
LeBlanc, Richard
Suzuki, Kenshi
Raab, Marc S.
Richardson, Paul G.
McKiver, Mihaela Popa
Jou, Ying-Ming
Yao, David
Das, Prianka
San-Miguel, Jesus
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 568 - +
[3] Elotuzumabplus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial
Dimopoulos, Meletios-Athanasios
Dytfeld, Dominik
Grosicki, Sebastian
Moreau, Philippe
Takezako, Naoki
Hori, Mitsuo
Leleu, Xavier
LeBlanc, Richard
Suzuki, Kenshi
Raab, Marc
Richardson, Paul G.
McKiver, Mihaela Popa
Jou, Ying-Ming
Yao, David
Das, Prianka
San-Miguel, Jesus F.
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S143 - S144
[4] Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study
Hori, Mitsuo
Takezako, Naoki
Sunami, Kazutaka
Ito, Shigeki
Kuroda, Junya
Popa-McKiver, Mihaela
Jou, Ying-Ming
Shelat, Suresh G.
Miyoshi, Masafumi
Suzuki, Kenshi
[J]. BLOOD, 2018, 132
[5] Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial
Dimopoulos, Meletios A.
Weisel, Katja
Lonial, Sagar
White, Darrell
Moreau, Philippe
Mateos, Maria-Victoria
San-Miguel, Jesus
Anderson, Kenneth C.
Shpilberg, Ofer
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Magen, Hila
Belch, Andrew
Reece, Donna
Beksac, Meral
Ganetsky, Alex
Jou, Ying-Ming
McKiver, Mihaela Popa
Singhal, Anil K.
Richardson, Paul G.
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E15 - E16
[6] Refractory Multiple Myeloma Doubling progression-free Survival for Elotuzumab in Combination with Pomalidomide and Dexamethasone in the ELOQUENT-3 Study
Freyer, Martina
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (7-8) : 390 - 391
[7] Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial
Weisel, Katja
Dimopoulos, Meletios A.
San-Miguel, Jesus
Paner, Agne
Engelhardt, Monika
Taylor, Fiona
Lord-Bessen, Jennifer
Yip, Christine
Greenwood, Mike
Tang, Jackson
Cavo, Michele
[J]. HEMASPHERE, 2023, 7 (03): : E843
[8] Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study
Dimopoulos, Meletios A.
Dytfeld, Dominik
Grosicki, Sebastian
Moreau, Philippe
Takezako, Naoki
Hori, Mitsuo
Leleu, Xavier
LeBlanc, Richard
Suzuki, Kenshi
Raab, Marc S.
Richardson, Paul G.
McKiver, Mihaela Popa
Jou, Ying-Ming
Shelat, Suresh G.
Robbins, Michael
Rafferty, Brian
San-Miguel, Jesus
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E164 - E165
[9] Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma ( RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial
Weisel, Katja
Dimopoulos, Meletios A.
San-Miguel, Jesus
Paner, Agne
Engelhardt, Monika
Taylor, Fiona
Lord-Bessen, Jennifer
Yao, David
Yip, Christine
Greenwood, Mike
Tang, Jackson
Cavo, Michele
[J]. BLOOD, 2021, 138
[10] Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study
Weisel, Katja
Paner, Agne
Engelhardt, Monika
Taylor, Fiona
Cocks, Kim
Popa-McKiver, Mihaela
Chen, Clara
Cavo, Michele
[J]. BLOOD, 2019, 134

← 1 2 3 4 5 →